Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer
Larson, Nicholas B. , Armasu, Sebastian M. , Fogarty, Zachary C. , McCauley, Brian M, Lawrenson, Kate , Gayther, Simon A. , Cunningham, Julie M. , Goode, Ellen L. , Lawrenson, Kate , Fogarty, Zachary C , Larson, Nicholas B , Winham, Stacey J. , Larson, Melissa C. , Wang, Chen , Fridley, Brooke L.

Mayo Clinic

Human Molecular Genetics | December 20, 2018 | Volume: 28 | Issue: 8 | Pages: 1331-1342

10.1093/hmg/ddy444 | PMID 30576442 Get It

AbstractX chromosome inactivation (XCI) is a key epigenetic gene expression regulatory process, which may play a role in women’s cancer. In particular tissues, some genes are known to escape XCI, yet patterns of XCI in ovarian cancer (OC) and their clinical associations are largely unknown. To examine XCI in OC, we integrated germline genotype with tumor copy number, gene expression and DNA methylation information from 99 OC patients. Approximately 10% of genes showed different XCI status (either escaping or being subject to XCI) compared with the studies of other tissues. Many of these genes are known oncogenes or tumor suppressors (e.g. DDX3X, TRAPPC2 and TCEANC). We also observed strong association between cis promoter DNA methylation and allele-specific expression imbalance (P = 2.0 × 10−10). Cluster analyses of the integrated data identified two molecular subgroups of OC patients representing those with regulated (N = 47) and dysregulated (N = 52) XCI. This XCI cluster membership was associated with expression of X inactive specific transcript (P = 0.002), a known driver of XCI, as well as age, grade, stage, tumor histology and extent of rl disease following surgical debulking. Patients with dysregulated XCI (N = 52) had shorter time to recurrence (HR = 2.34, P = 0.001) and overall survival time (HR = 1.87, P = 0.02) than those with regulated XCI, although results were attenuated after covariate adjustment. Similar findings were observed when restricted to high-grade serous tumors. We found evidence of a unique OC XCI profile, suggesting that XCI may play an important role in OC biology. Additional studies to examine somatic changes with paired tumor-normal tissue are needed.
A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative
Kuang, Liqun , Han, Xie , Chen, Kewei , Caselli, Richard J. , Reiman, Eric M. , Wang, Yalin , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R. , Levey, Allan I. , Kantarci, Kejal , Mathis, Chester A. , Donohue, Michael , DeCarli, Charles , Preda, Adrian , Carrillo, María C. , Turner, Raymond Scott , Bartha, Robert , Pomara, Nunzio , Sadowski, Martin , Arfanakis, Konstantinos , Lamar, Melissa , DeCarli, Charles , Jack, Clifford R , Preda, Adrian , Kantarci, Kejal , Donohue, Michael C , Initiative, for the Alzheimer's Disease Neuroimaging, Wang, Yalin , Levey, Allan I , Jimenez‐Maggiora, Gustavo Adolfo

Mayo Clinic

Human Brain Mapping | December 20, 2018 | Volume: 40 | Issue: 4 | Pages: 1062-1081

10.1002/hbm.24383 | PMID 30569583 Get It

AbstractAlzheimer's disease (AD) is the most common type of dementia in the elderly with no effective treatment currently. Recent studies of noninvasive neuroimaging, resting‐state functional magnetic resonance imaging (rs‐fMRI) with graph theoretical analysis have shown that patients with AD and mild cognitive impairment (MCI) exhibit disrupted topological organization in large‐scale brain networks. In previous work, it is a common practice to threshold such networks. However, it is not only difficult to make a principled choice of threshold values, but also worse is the discard of potential important information. To address this issue, we propose a threshold‐free feature by integrating a prior persistent homology‐based topological feature (the zeroth Betti number) and a newly defined connected component aggregation cost feature to model brain networks over all possible scales. We show that the induced topological feature (Integrated Persistent Feature) follows a monotonically decreasing convergence function and further propose to use its slope as a concise and persistent brain network topological measure. We apply this measure to study rs‐fMRI data from the Alzheimer's Disease Neuroimaging Initiative and compare our approach with five other widely used graph measures across five parcellation schemes ranging from 90 to 1,024 region‐of‐interests. The experimental results demonstrate that the proposed network measure shows more statistical power and stronger robustness in group difference studies in that the absolute values of the proposed measure of AD are lower than MCI and much lower than normal controls, providing empirical evidence for decreased functional integration in AD dementia and MCI.
Different Transcriptome Profiles between Human Retinoblastoma Y79 Cells and an Etoposide-resistant Subline Reveal a Chemoresistance Mechanism
Song, Wenping , Zheng, Si , Yao, Hong-Juan, Zhou, Xiaofei , Zhang, Chengyue , Zhao, Junyang , Wang, Liewei , Shao, Rong‐Guang , Li, Rui P. , Li, Liang

Mayo Clinic

No container title available | December 20, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.135/v1 Get It

Abstract Background: Retinoblastoma (RB) is the most frequent pediatric retinal tumor. In the present study, to elucidate chemoresistance mechanisms and identify potential biomarkers in RB, we utilized RNA sequencing (RNAseq) technological platforms to reveal transcriptome profiles and identify any differentially expressed genes (DEGs) between an etoposide drug-resistant subline (Y79/EDR) and parental Y79 cells. Methods: To test whether Y79/EDR cells showed resistance to antineoplastic agents for RB, we treated the cells with etoposide, carboplatin and vincristine and analyzed them with a Cell Counting Kit-8 (CCK-8). Y79/EDR and parental Y79 cells were used for RNAseq and bioinformatics analysis to enable a genome-wide review of DEGs between the two lines using the DESeq R package (1.10.1). Then, DEG enrichment in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was analyzed with KOBAS software. Next, real-time quantitative polymerase chain reaction (QRT-PCR) and cytotoxicity assays were performed to experimentally and functionally validate the identified candidate biomarkers. Results: Y79/EDR cells showed resistance to etoposide, carboplatin and vincristine at different concentrations. In total, 524 transcripts were differentially expressed in Y79/EDR cells based on analysis of fragments per kilobase of transcript per million fragments mapped (FPKM); among these, 57 genes were downregulated and 467 genes were upregulated in Y79/EDR cells compared to parental Y79 cells. We selected candidate DEGs, including ARHGAP9, HIST1H4H, RELN, DDIT4, HK2, STC1 and PFKFB4, for mRNA expression validation with QRT-PCR assays and found that the expression levels determined by QRT-PCR were consistent with the RNAseq data. Further studies involving downregulation of ARHGAP9 with a specific siRNA pool showed that ARHGAP9 altered the cellular sensitivity of Y79 cells to etoposide and carboplatin. Conclusion: Our initial findings provided a genomic view of the transcription profiles of etoposide-induced acquired resistance in RB. Follow-up studies indicated that ARHGAP9 might be a chemoresistance biomarker in RB, providing insight into potential therapeutic targets for overcoming acquired chemoresistance in RB. These findings can aid in understanding and overcoming chemoresistance during treatment of RB in the clinic.
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Mandrekar, Sumithra J. , Laumann, Kristina, Walker, Alison R. , Wang, Eunice S. , Kolitz, Jonathan E. , Powell, Bayard L., Attar, Eyal C. , Bloomfield, Clara D. , Kohlschmidt, Jessica, Mrózek, Krzysztof , Garraway, Levi A. , Jané‐Valbuena, Judit , Baltay, Michele , Tracy, Adam , Marcucci, Guido , Stone, Richard M. , Wang, Eunice S. , Roboz, Gail J. , Desai, Pinkal , Stock, Wendy , Hassane, Duane C. , Larson, Richard A.

Mayo Clinic

Blood Advances | December 19, 2018 | Volume: 2 | Issue: 24 | Pages: 3608-3617

10.1182/bloodadvances.2018023689 | PMID 30567725 Get It

Abstract Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine on days 1 to 10 alone (arm A) with those of 1.3 mg/m2 of subcutaneous bortezomib (arm B) on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles. Previously untreated AML patients age ≥60 years (excluding those with FLT3 mutations and favorable-risk cytogenetics) without restrictions in performance status (PS) or organ function were eligible. Median age was 72.4 years (range, 60.5-92.3 years); 31 patients (19%) had baseline PS ≥2, 35 (22%) had an antecedent hematological disorder, 58 had (39%) adverse cytogenetics, and 7 (5%) and 23 (14%) had abnormal cardiac or renal function. There were no statistically significant differences in overall survival (OS) or responses between the 2 treatment arms. The overall response rate (complete remission + complete remission with incomplete blood count recovery) was 39% (n = 64), with median OS of 9.3 months. Nineteen responders (31%) underwent allogeneic stem cell transplantation. The most common adverse event was febrile neutropenia, and there were no unexpected toxicities. Adding bortezomib to decitabine did not improve outcomes, but responses were better than those in previous trials using 5-day decitabine cycles. This trial was registered at www.clinicaltrials.gov as #NCT01420926.
995: WHERE IS THAT LINE? AN UNUSUAL CASE OF A MALPOSITIONED CENTRAL VENOUS CATHETER
Wang, Yuxiang , Egan, Ashley M. , Hoskote, Sumedh S.

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 476-476

10.1097/01.ccm.0000551743.74233.52 Get It

The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution
Zhao, Li , Lu, Meng , Nie, Xiaomin , Abudukerimu, Buatikamu, Zhang, Kun , Ning, Zhiyuan, Chen, Yi , Cheng, Jing , Xia, Fangzhen , Wang, Ningjian , Jensen, Michael D. , Lu, Yingli , Zhu, Chunfang , Chen, Chi

Mayo Clinic

Journal of Endocrinology | December 18, 2018 | Volume: 240 | Issue: 2 | Pages: 271-286

10.1530/joe-18-0374 | PMID 30530905 Get It

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an ideal therapy for type 2 diabetes and, as of recently, for obesity. In contrast to visceral fat, subcutaneous fat appears to be protective against metabolic diseases. Here, we aimed to explore whether liraglutide, a GLP-1RA, could redistribute body fat via regulating lipid metabolism in different fat depots. After being fed a high-fat diet for 8 weeks, 50 male Wistar and Goto-Kakizaki rats were randomly divided into a normal control group, a diabetic control group, low- and high-dose liraglutide-treated groups and a diet-control group. Different doses of liraglutide (400 μg/kg/day or 1200 μg/kg/day) or an equal volume of normal saline were administered to the rats subcutaneously once a day for 12 weeks. Body composition and body fat deposition were measured by dual-energy X-ray absorptiometry and MRI. Isotope tracers were infused to explore lipid metabolism in different fat depots. Quantitative real-time PCR and Western blot analyses were conducted to evaluate the expression of adipose-related genes. The results showed that liraglutide decreased visceral fat and relatively increased subcutaneous fat. Lipogenesis was reduced in visceral white adipose tissue (WAT) but was elevated in subcutaneous WAT. Lipolysis was also attenuated, and fatty acid oxidation was enhanced. The mRNA expression levels of adipose-related genes in different tissues displayed similar trends after liraglutide treatment. In addition, the expression of browning-related genes was upregulated in subcutaneous WAT. Taken together, the results suggested that liraglutide potentially redistributes body fat and promotes browning remodeling in subcutaneous WAT to improve metabolic disorders.
Transcriptome and epigenome landscape of human cortical development modeled in organoids
Amiri, Anahita , Coppola, Gianfilippo , Scuderi, Soraya , Wu, Feinan , Roychowdhury, Tanmoy , Liu, Fuchen , Pochareddy, Sirisha , Shin, Yurae , Safi, Alexias , Song, Lingyun , Sousa, André M. M. , Crawford, Gregory E. , Šestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M. , An, Joon‐Yong , Armoskus, Christoper, Beach, Thomas G., Belmont, Judson, Bendl, Jaroslav , Borrman, Tyler , Brown, Leanne, Brown, Miguel , Brown, Mimi, Brunetti, Tonya M. , Burke, Emily E., Chae, Yooree, Charney, Alexander W. , Cherskov, Adriana , Choi, Jinmyung , Clarke, Declan , Valle, Diane M. Del , Devillers, Olivia, Dracheva, Stella , Emani, Prashant S. , Evgrafov, Oleg V. , Fitzgerald, Dominic , Flatow, Elie, Francoeur, Nancy , Fullard, John F. , Gao, Tianliuyun , Geschwind, Daniel H. , Giase, Gina , Goodman, Thomas, Grennan, Kay, Gu, Mengting , Hadjimichael, Evi , Hahn, Chang-Gyu, Haroutunian, Vahram , Huey, Jack , Ivanov, Nikolay A. , Jacobov, Rivka, Jiang, Yan , Jiang, Yi , Kassim, Bibi, Kefi, Amira , Kleiman, Joel E., Knowles, James A. , Kozlenkov, Alexey , Li, Zhen , Lipska, Barbara K., Mangravite, Lara M. , Mariani, Jessica , Mattei, Eugenio , Miller, Daniel J. , Moore, J. Russell, Peters, Mette A. , Pinto, Dalila , Polioudakis, Damon, Ray, Mohana, Reddy, Timothy E. , Rhie, Suhn K. , Santpere, Gabriel , Sheppard, Brooke , Shi, Xu , Shieh, Annie W. , Shin, Joo Heon , Spitsyna, Valeria N. , Szatkiewicz, Jin , Szekely, Anna , Wang, Yongjun , Weissman, Sherman M., Weng, Zhiping , White, Kevin P. , Willsey, Jeremy A., Witt, Heather , Won, Hyejung , Xia, Yan , Xu, Min , Yang, Mo , Zandi, Peter P. , Zhang, Jing , Zharovsky, Elizabeth , Sousa, André M M , Gerstein, Mark , Crawford, Gregory E , Sestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M , Del Valle, Diane M , Zhu, Ying , Gerstein, Mark , Akbarian, Schahram , Ashley‐Koch, Allison E. , Bryois, Julien , Camarena, Adrian , Carlyle, Becky Catherine , Chen, Chao , Cheng, Lijun , Collado‐Torres, Leonardo , Dai, Rujia , Torre-Ubieta, Luis de la , Farnham, Peggy , Gandal, Michael J. , Garrett, Melanie E , Girdhar, Kiran Kumar , Giusti‐Rodríguez, Paola , Goes, Fernando , Goodman, Thomas, Gürsoy, Gamze , Hauberg, Mads E. , Hoffman, Gabriel E. , Hyde, Thomas M , Jaffe, Andrew E. , Johnson, Graham D. , Kim, Yunjung , Kitchen, Robert , Li, Mingfeng , Liu, Chunyu , Liu, Shuang , Moore, Jill, Nairn, Angus C. , Navarro, Fábio C. P. , Park, Royce , Pratt, Henry , Price, Amanda J. , Purcaro, Michael J. , Roussos, Panos , Sanders, Stephan , Schreiner, Shannon , Škarica, Mario , State, Matthew W. , Sullivan, Patrick F. , Swarup, Vivek , Tao, Ran , Bakel, Harm van , Wang, Daifeng , Warrell, Jonathan , Webster, Maree J. , Werling, Donna M. , Wiseman, Jennifer R. , Wray, Gregory A. , Yang, Yucheng

Mayo Clinic

Science | December 13, 2018 | Volume: 362 | Issue: 6420 | Pages: No page available

10.1126/science.aat6720 | PMID 30545853 Get It

INTRODUCTION The human cerebral cortex has undergone an extraordinary increase in size and complexity during mammalian evolution. Cortical cell lineages are specified in the embryo, and genetic and epidemiological evidence implicates early cortical development in the etiology of neuropsychiatric disorders such as autism spectrum disorder (ASD), intellectual disabilities, and schizophrenia. Most of the disease-implicated genomic variants are located outside of genes, and the interpretation of noncoding mutations is lagging behind owing to limited annotation of functional elements in the noncoding genome. RATIONALE We set out to discover gene-regulatory elements and chart their dynamic activity during prenatal human cortical development, focusing on enhancers, which carry most of the weight upon regulation of gene expression. We longitudinally modeled human brain development using human induced pluripotent stem cell (hiPSC)–derived cortical organoids and compared organoids to isogenic fetal brain tissue. RESULTS Fetal fibroblast–derived hiPSC lines were used to generate cortically patterned organoids and to compare oganoids’ epigenome and transcriptome to that of isogenic fetal brains and external datasets. Organoids model cortical development between 5 and 16 postconception weeks, thus enabling us to study transitions from cortical stem cells to progenitors to early neurons. The greatest changes occur at the transition from stem cells to progenitors. The regulatory landscape encompasses a total set of 96,375 enhancers linked to target genes, with 49,640 enhancers being active in organoids but not in mid-fetal brain, suggesting major roles in cortical neuron specification. Enhancers that gained activity in the human lineage are active in the earliest stages of organoid development, when they target genes that regulate the growth of radial glial cells. Parallel weighted gene coexpression network analysis (WGCNA) of transcriptome and enhancer activities defined a number of modules of coexpressed genes and coactive enhancers, following just six and four global temporal patterns that we refer to as supermodules, likely reflecting fundamental programs in embryonic and fetal brain. Correlations between gene expression and enhancer activity allowed stratifying enhancers into two categories: activating regulators (A-regs) and repressive regulators (R-regs). Several enhancer modules converged with gene modules, suggesting that coexpressed genes are regulated by enhancers with correlated patterns of activity. Furthermore, enhancers active in organoids and fetal brains were enriched for ASD de novo variants that disrupt binding sites of homeodomain, Hes1, NR4A2, Sox3, and NFIX transcription factors. CONCLUSION We validated hiPSC-derived cortical organoids as a suitable model system for studying gene regulation in human embryonic brain development, evolution, and disease. Our results suggest that organoids may reveal how noncoding mutations contribute to ASD etiology. Summary of the study, analyses, and main results. Data were generated for iPSC-derived human telencephalic organoids and isogenic fetal cortex. Organoids modeled embryonic and early fetal cortex and show a larger repertoire of enhancers. Enhancers could be divided into activators and repressors of gene expression. We derived networks of modules and supermodules with correlated gene and enhancer activities, some of which were implicated in autism spectrum disorders (ASD).
Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients
Obraztsov, I. V. , Широких, К. Е., Obraztsova, Olga Isaakovna, Шапина, М. В. , Wang, Ming‐Hsi , Халиф, И. Л. , Исааковна, Образцова Ольга

Mayo Clinic

Inflammatory Bowel Diseases | December 13, 2018 | Volume: 25 | Issue: 3 | Pages: 524-531

10.1093/ibd/izy358 | PMID 30544140 Get It

Conceptualising paediatric health disparities: a metanarrative systematic review and unified conceptual framework
Ridgeway, Jennifer L. , Ryn, Michelle van , Murad, M. Hassan , Asiedu, Gladys B. , Egginton, Jason S. , Beebe, Timothy J. , Finney Rutten, Lila J, van Ryn, Michelle, Griffin, Joan M. , Murad, M Hassan , Ridgeway, Jennifer L , van Ryn, Michelle , Wang, Zhen , Rutten, Lila J. Finney , Beebe, Timothy J.

Mayo Clinic

BMJ Open | December 11, 2018 | Volume: 7 | Issue: 8 | Pages: e015456

10.1136/bmjopen-2016-015456 | PMID 28780545 Get It

Objective There exists a paucity of work in the development and testing of theoretical models specific to childhood health disparities even though they have been linked to the prevalence of adult health disparities including high rates of chronic disease. We conducted a systematic review and thematic analysis of existing models of health disparities specific to children to inform development of a unified conceptual framework. Methods We systematically reviewed articles reporting theoretical or explanatory models of disparities on a range of outcomes related to child health. We searched Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus (database inception to 9 July 2015). A metanarrative approach guided the analysis process. Results A total of 48 studies presenting 48 models were included. This systematic review found multiple models but no consensus on one approach. However, we did discover a fair amount of overlap, such that the 48 models reviewed converged into the unified conceptual framework. The majority of models included factors in three domains: individual characteristics and behaviours (88%), healthcare providers and systems (63%), and environment/community (56%), . Only 38% of models included factors in the health and public policies domain. Conclusions A disease-agnostic unified conceptual framework may inform integration of existing knowledge of child health disparities and guide future research. This multilevel framework can focus attention among clinical, basic and social science research on the relationships between policy, social factors, health systems and the physical environment that impact children's health outcomes.